Medace achieves ambitions at Brightlands

may 23, 2019

Medace BV is a start-up that helps bring medical innovations to patients faster and more efficiently. This company will be moving to Brightlands Maastricht Health Campus in January 2020. The high degree of confidence in the possibilities Medace has to offer is evidenced by the 7.4 million Euros that the company “collected” to realize its ambitions.

The concept behind Medace was born at the Chemelot InSciTe knowledge institute at the Brightlands Chemelot Campus in Sittard-Geleen. Medace’s potential for growth based on this concept will be achieved thanks to investments from Brightlands Maastricht Health Campus, Brightlands Chemelot Campus, LIOF (Limburg Development and Investment Company), Maastricht University, Maastricht UMC+ and the Province of Limburg. 

Development projects

Starting on January 1, 2020, Medace will be able to oversee 20 companies or academic development projects simultaneously from the new location. Focused on developing biomedical materials, implants, cell therapy and combined (regenerative medicine) products, Medace’s goal is for its concept to become a solution to the normally high development costs and complex legislation and regulations. To do this, Medace will have access to a complete ISO-certified work environment with a quality management system, cleanroom, office infrastructure, equipment and facilities for holding training programs with professionals.

Medace CEO Danielle Curfs: “We have developed a model that offers all of the necessary production elements as options in a menu. You buy what you need for the phase your production development is in at that moment, from infrastructure to people. All of this is ISO-certified, which means that you can serve a much larger group with significantly fewer resources. We are convinced that the path that ultimately leads to the patient will become less complex and good ideas will actually be implemented. There is also a huge learning aspect involved since everyone runs into similar problems.”

Brightlands Maastricht Health Campus CEO Jan Cobbenhagen: “Medace is a valuable asset for reinforcing the Brightlands biomedical ecosystem. It creates a connection between the activities at the Brightlands Maastricht Health Campus that focus on regenerative medicine and other areas and the valorisation of inventions to those occurring at the Brightlands Chemelot Campus. The full-service matrix proposition that Medace offers to our biomedical start-ups helps them simplify and accelerate the transition from patent to patient. This in turn helps us significantly increase these start-ups’ chance of success.”

Brightlands Chemelot Campus CEO Bert Kip: “Developments in the biomedical field are moving at breakneck speed. Medace is one of the strong crossovers at Brightlands; this time, the partnership is between the Brightlands Maastricht Health Campus and the Brightlands Chemelot Campus. Medace is a crucial step in optimizing innovations to get them to the first-in-man phase. It represents an important reinforcement of the Brightlands biomedical ecosystem.”

About Medace

Medace offers a full-service work-study environment in which clients (academics or entrepreneurs) receive support in setting up and developing the technical documentation necessary to the clinical validation process while they work on producing their high-quality clinical product.

Medace works with an EN ISO 13485: 2016 certified quality and service package that is available for clients based on their needs.

Medace offers:

  • Specialized infrastructure (including ISO 7 and 8, and class C and B cleanrooms)
  • Validated, specialized equipment
  • Quality-control system
  • Trained professionals for hands-on supervision and support
  • Dedicated internal training programs

 For further information on Medace: www.medacespace.com

 

  overview news & events

Medace BV, een start-up die helpt medische innovaties sneller en efficiënter naar de patiënt te brengen, verhuist in januari 2020 naar Brightlands Maastricht Health Campus. Het vertrouwen in de mogelijkheden van Medace is groot, getuige de 7,4 miljoen euro die het bedrijf heeft ‘opgehaald’ om de ambities te kunnen verwezenlijken.

Lees dit artikel in het Nederlands